Vendor scorecard

Empower Pharmacy

62/100
Conditional
United States · 503B + 503A compounding pharmacy (Houston, TX) · FDA-registered 503B outsourcing facility + 503A compounder; backend pharmacy for many telehealth GLP-1 platforms

Empower Pharmacy scored 62/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee — never pay-to-rank. Below is the full per-signal breakdown.

Visit Empower Pharmacy →Read the rubricGet your match
11-signal breakdown
  • COA on every lot
    503B per-batch testing required; April 2025 FDA warning letter cited gaps in microbial-excursion investigation
    75
  • Cold-chain verified
    503B sterile production standard; FDA warning letter flagged sterile-drug production deficiencies at two Houston facilities
    70
  • Rx legality
    Rx-required, multi-state licensed; Lilly tirzepatide lawsuit ongoing in Texas federal court (refiled July 2025)
    75
  • Compound identity
    75
  • Dose accuracy
    FDA warning letter cited labeling omissions that disqualified some 503B exemptions
    70
  • Endotoxin testing
    503B requires testing; FDA warning letter cited inadequate investigation of microbial excursions
    70
  • Refund posture
    prescription-fulfillment model; refund handled via partner clinic
    55
  • Channel clarity
    Rx-only via partner clinic; backend pharmacy for many GLP-1 telehealth platforms
    80
  • Support quality
    support routed through prescribing clinic
    60
  • Price transparency
    set by partner clinic; not directly listed on Empower site
    50
  • Longitudinal retention
    high volume during 2023-2025 GLP-1 shortage; Lilly suit + April 2025 FDA letter active overhang
    70
Supply where Empower Pharmacy operates
Mounjaro
Stable

Brand stable post-Feb-Mar 2026 reclass. Compounded path narrowed under FDA personalisation rules but 503A pharmacies and major telehealth (Henry, Mochi, Ro) still ship.

5d ago
Ozempic
Stable

Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.

5d ago
Rybelsus
Stable

Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.

5d ago
Wegovy
Stable

Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans.

5d ago
Zepbound
Stable

Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable.

5d ago
Full supply tracker across all regions →
Sources we audited against
How we score

The 11-signal rubric is public.

Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out — they don't appear in our match flow at all.

If Empower Pharmacy wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.

Full methodology →

Want a match for your situation?

Take the 2-minute quiz. We'll match you against this and the other vendors in your region — based on your dose, urgency, and budget.

Take the quiz

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.